Table 2. Diseases included in analyses using HLMrefined and details of customizations, New York City, New York, USA, May 20–August 5, 2013*.
| Disease | Minimum no. cases in UHF neighborhood to qualify for signal | Further customization |
|---|---|---|
| Amebiasis | 5 | |
| Anaplasmosis (human granulocytic) | 3 | |
| Babesiosis | 3 | |
| Campylobacteriosis | 8 | |
| Cholera | 3 | |
| Cryptosporidiosis | 5 | |
| Cyclosporiasis | 3 | |
| Dengue | 3 | |
| Ehrlichiosis (human monocytic) | 3 | |
| Giardiasis | 5 | |
| Haemophilus influenzae disease, invasive | 3 | |
| Hemolytic uremic syndrome | 3 | |
| Hepatitis A | 5 | |
| Hepatitis B (acute) | 2† | |
| Hepatitis D | 2† | |
| Hepatitis E | 2† | |
| Legionellosis | 5 | |
| Listeriosis | 3 | |
| Malaria | 3 | |
| Meningitis, bacterial | 4 | |
| Meningitis, viral (aseptic) | 3 | |
| Meningococcal disease (Neisseria meningitidis) | 3 | |
| Paratyphoid fever | 3 | |
| Rickettisalpox | 3 | |
| Rocky Mountain spotted fever | 3 | Restrict analysis to confirmed, probable, and suspected cases and implement a 4-wk lag to allow for data accrual |
| Shiga toxin–producing Escherichia coli (including E. coli O157:H7) infection | 3 | |
| Shigellosis | 10 | |
| Staphylococcus aureus infection, vancomycin intermediate | 3 | |
| Streptococcus (group A) disease, invasive | 5 | Restrict analysis to confirmed, probable, suspected, and pending cases |
| Streptococcus (group B) disease, invasive | 5 | |
| Streptococcus pneumoniae disease, invasive | 5 | |
| Typhoid fever | 3 | |
| Vibrio spp. infection, noncholera (including parahaemolyticus and vulnificus) | 3 | |
| West Nile disease | 3 | |
| Yersiniosis | 3 |
* HLMrefined, refined method applied starting May 20, 2013; UHF, United Hospital Fund. †These are the only diseases for which the signaling threshold was decreased below 3 cases.